Evidence map›Paper›PMID 34272580›Full record

ArticleDiabetologia2021

DR15-DQ6 remains dominantly protective against type 1 diabetes throughout the first five decades of life.

Nicholas J Thomas, John M Dennis, Seth A Sharp, Akaal Kaur, Shivani Misra, Helen C Walkey, Desmond G Johnston, Nick S Oliver, William A Hagopian, Michael N Weedon and 2 more

Erratum issued Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Diabetologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06006468 (Evaluating ImmuNe Changes in the Evolution of Pre Type 1 Diabetes With Adult Onset), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06006468 completednot on this mapstarted 2023, after this paper: background citation

Evaluating ImmuNe Changes in the Evolution of Pre Type 1 Diabetes With Adult Onset

TypeobservationalSponsorRoyal Devon and Exeter NHS Foundation TrustRan2023 to 2023Enrolled2,250ConditionsType 1 Diabetes, Type 1 Diabetes Mellitus Maturity OnsetArmsHigh genetic risk for type 1 diabetes, High gentic risk for Coeliac disease
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Nicholas J ThomasInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK. n.thomas3@exeter.ac.uk.ORCID 0000-0003-2513-7022
John M DennisInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.ORCID 0000-0002-7171-732X
Seth A SharpInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.ORCID 0000-0002-0607-9990
Akaal KaurFaculty of Medicine, Imperial College, London, UK.
Shivani MisraFaculty of Medicine, Imperial College, London, UK.ORCID 0000-0003-2886-0726
Helen C WalkeyFaculty of Medicine, Imperial College, London, UK.ORCID 0000-0003-3391-0759
Desmond G JohnstonFaculty of Medicine, Imperial College, London, UK.ORCID 0000-0001-9539-7108
Nick S OliverFaculty of Medicine, Imperial College, London, UK.ORCID 0000-0003-3525-3633
William A HagopianPacific Northwest Research Institute, Seattle, WA, USA.ORCID 0000-0003-2979-0475
Michael N WeedonInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.ORCID 0000-0002-6174-6135
Kashyap A PatelInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.ORCID 0000-0002-9240-8104
Richard A OramInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK. r.oram@exeter.ac.uk.ORCID 0000-0003-3581-8980
University of Exeter · GBImperial College London · GBPacific Northwest Diabetes Research Institute · US

Funding

Indiana University clinical Center for acute pancreatitis and diabetes clinical research networkU01DK127382 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Carmella Evans-Molina, Evan L Fogel · 2020 to 2026
$2.4M
Department of HealthMedical Research Council MC_PC_17228Medical Research Council MC_QA137853NIDDK NIH HHS U01 DK127382Wellcome Trust 219606/Z/19/ZWellcome Trust 220601/Z/20/ZWellcome Trust WT097835MF
6 · The paper itself

Abstract

aims/hypothesisAmong white European children developing type 1 diabetes, the otherwise common HLA haplotype DR15-DQ6 is rare, and highly protective. Adult-onset type 1 diabetes is now known to represent more overall cases than childhood onset, but it is not known whether DR15-DQ6 is protective in older-adult-onset type 1 diabetes. We sought to quantify DR15-DQ6 protection against type 1 diabetes as age of onset increased.

methodsIn two independent cohorts we assessed the proportion of type 1 diabetes cases presenting through the first 50 years of life with DR15-DQ6, compared with population controls. In the After Diabetes Diagnosis Research Support System-2 (ADDRESS-2) cohort (n = 1458) clinician-diagnosed type 1 diabetes was confirmed by positivity for one or more islet-specific autoantibodies. In UK Biobank (n = 2502), we estimated type 1 diabetes incidence rates relative to baseline HLA risk for each HLA group using Poisson regression. Analyses were restricted to white Europeans and were performed in three groups according to age at type 1 diabetes onset: 0-18 years, 19-30 years and 31-50 years.

resultsDR15-DQ6 was protective against type 1 diabetes through to age 50 years (OR < 1 for each age group, all p < 0.001). The following ORs for type 1 diabetes, relative to a neutral HLA genotype, were observed in ADDRESS-2: age 5-18 years OR 0.16 (95% CI 0.08, 0.31); age 19-30 years OR 0.10 (0.04, 0.23); and age 31-50 years OR 0.37 (0.21, 0.68). DR15-DQ6 also remained highly protective at all ages in UK Biobank. Without DR15-DQ6, the presence of major type 1 diabetes high-risk haplotype (either DR3-DQ2 or DR4-DQ8) was associated with increased risk of type 1 diabetes. CONCLUSIONS/

interpretationHLA DR15-DQ6 confers dominant protection from type 1 diabetes across the first five decades of life.

Indexed as

AdolescentAdultAge of OnsetAutoantibodiesCase-Control StudiesChildChild, PreschoolCohort StudiesDiabetes Mellitus, Type 1FemaleGenotypeHLA-DQ AntigensHLA-DR Serological SubtypesHumansInfantInfant, NewbornAutoantibodiesHLA-DQ6 antigenHLA-DQ AntigensHLA-DR15 antigenHLA-DR Serological SubtypesAdult onset type 1 diabetesDR15-DQ6Genetic predispositionGenetic protectionGenetic resistanceHLAType 1 diabetes

Identifiers

PMID34272580
PMCPMC8423681
OpenAlexW3179089832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.